Physician profile
Oscar E Streeter
NPI 1083764963
$2,264.90
in general payments reported to CMS, 2019-2025
20 companies · $244 in 2025
The $244 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $416 · 2020: $904 · 2022: $140 · 2023: $121 · 2024: $439 · 2025: $244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $726 · Education: $79.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $725.65 |
| Education | $79.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $871.86 | 2020 | |
| Elekta, INC. | $242.37 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $217.53 | 2019-2025 | Imfinzi, Enhertu |
| Merck Sharp & Dohme LLC | $170.71 | 2019-2025 | Keytruda, Lynparza, Reblozyl |
| Genzyme Corporation | $135.42 | 2019 | |
| Tactile Systems Technology INC | $109.72 | 2022 | |
| Lilly USA, LLC | $96.86 | 2023-2024 | Jaypirca, Verzenio, Retevmo |
| Gilead Sciences, INC. | $89.05 | 2024-2025 | Trodelvy |
| Alexion Pharmaceuticals, INC. | $42.79 | 2024-2025 | Ultomiris |
| Eisai INC. | $40.67 | 2025 | |
| Genentech USA, INC. | $35.70 | 2024-2025 | Tecentriq |
| Incyte Corporation | $34.09 | 2023-2024 | Jakafi |
| Reflexion Medical, INC. | $30.16 | 2022 | |
| Amgen INC. | $26.41 | 2023 | |
| Daiichi Sankyo INC. | $25.91 | 2023 | Enhertu |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coherus Oncology, INC. | $25.05 | 2023 | |
| Celgene Corporation | $18.09 | 2024 | Reblozyl |
| E.R. Squibb & Sons, L.L.C. | $17.90 | 2024 | Opdivo |
| Novartis Pharmaceuticals Corporation | $17.84 | 2020 | |
| Janssen Biotech, INC. | $16.77 | 2025 | Talvey, Darzalex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oscar Streeter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.